Collectively, these data pharmacologically validate the findings of BCL2 sensitization identified in our CREBBP-mutated cell lines and support a possible drug combination for clinical translation in B-ALL more broadly. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.